共查询到20条相似文献,搜索用时 0 毫秒
1.
San-Yuan Ma Yuan-Yuan Liu Wei Lu Xiao-Gang Wang Le Sun Kai Yu Qing-You Xia 《Insect Science》2019,26(6):1055-1058
Dear Editor, Artificial expression systems are crucial to functional genomics studies, constructing synthetic genetic circuits, and bioengineering (Werner & Gossen, 2014). They are usually achieved by cloning the coding sequence (CDS) of a target gene into a vector containing natural or engineered regulatory elements. However, this strategy is limited when target genes are hard to clone, for example when the CDS is too long, or expression level is too low. 相似文献
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
《MABS-AUSTIN》2013,5(2):303-310
Macrophages are innate immune cells that derive from circulating monocytes, reside in all tissues, and participate in many states of pathology. Macrophages play a dichotomous role in cancer, where they promote tumor growth but also serve as critical immune effectors of therapeutic antibodies. Macrophages express all classes of Fcγ receptors, and they have immense potential to destroy tumors via the process of antibody-dependent phagocytosis. A number of studies have demonstrated that macrophage phagocytosis is a major mechanism of action of many antibodies approved to treat cancer. Consequently, a number of approaches to augment macrophage responses to therapeutic antibodies are under investigation, including the exploration of new targets and development of antibodies with enhanced functions. For example, the interaction of CD47 with signal-regulatory protein α (SIRPα) serves as a myeloid-specific immune checkpoint that limits the response of macrophages to antibody therapies, and CD47-blocking agents overcome this barrier to augment phagocytosis. The response of macrophages to antibody therapies can also be enhanced with engineered Fc variants, bispecific antibodies, or antibody-drug conjugates. Macrophages have demonstrated success as effectors of cancer immunotherapy, and further investigation will unlock their full potential for the benefit of patients. 相似文献
18.
Macrophages are innate immune cells that derive from circulating monocytes, reside in all tissues, and participate in many states of pathology. Macrophages play a dichotomous role in cancer, where they promote tumor growth but also serve as critical immune effectors of therapeutic antibodies. Macrophages express all classes of Fcγ receptors, and they have immense potential to destroy tumors via the process of antibody-dependent phagocytosis. A number of studies have demonstrated that macrophage phagocytosis is a major mechanism of action of many antibodies approved to treat cancer. Consequently, a number of approaches to augment macrophage responses to therapeutic antibodies are under investigation, including the exploration of new targets and development of antibodies with enhanced functions. For example, the interaction of CD47 with signal-regulatory protein α (SIRPα) serves as a myeloid-specific immune checkpoint that limits the response of macrophages to antibody therapies, and CD47-blocking agents overcome this barrier to augment phagocytosis. The response of macrophages to antibody therapies can also be enhanced with engineered Fc variants, bispecific antibodies, or antibody-drug conjugates. Macrophages have demonstrated success as effectors of cancer immunotherapy, and further investigation will unlock their full potential for the benefit of patients. 相似文献
19.
20.
An engineered promoter driving expression of a microbial avirulence gene confers recognition of TAL effectors and reduces growth of diverse Xanthomonas strains in citrus 下载免费PDF全文
Deepak Shantharaj Patrick Römer Jose F. L. Figueiredo Gerald V. Minsavage Christina Krönauer Robert E. Stall Gloria A. Moore Latanya C. Fisher Yang Hu Diana M. Horvath Thomas Lahaye Jeffrey B. Jones 《Molecular Plant Pathology》2017,18(7):976-989